Perioperative tislelizumab plus chemo for esophageal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests whether giving tislelizumab (an immunotherapy) along with chemotherapy before and after surgery can help people with a type of esophageal cancer called squamous cell carcinoma. The goal is to see if this combination improves outcomes for patients whose cancer is in the chest and can be removed with surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have squamous cell carcinoma of the esophagus located in the chest area.
- Your cancer has not been treated with any systemic therapy (like chemo) or local therapy before.
- You are between 18 and 75 years old.
- You are in good overall health (ECOG score 0-1) and have adequate heart, lung, liver, kidney, and bone marrow function.
- You are willing and able to follow the study plan and attend follow-up visits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests giving the immunotherapy drug sintilimab together with chemotherapy before and after surgery for esophageal squamous cell carcinoma. It aims to see if this combination can help improve outcomes for patients whose tumors can be surgically removed.
This trial tests whether adding the immunotherapy drug tislelizumab to standard chemotherapy after surgery can help prevent esophageal cancer from coming back. It is for people whose cancer had spread to lymph nodes at the time of surgery.
This trial tests a combination of the immunotherapy drug tislelizumab and the chemotherapy drug S-1 for people with a specific type of esophageal cancer that still has some cancer cells in the main tumor but no cancer in lymph nodes after surgery. The goal is to see if this treatment can help prevent the cancer from coming back.
This trial tests whether adding tislelizumab to chemoradiation as the first treatment helps people with advanced esophageal squamous cell cancer. It aims to improve how well the cancer responds when it cannot be cured with surgery or full-dose curative treatment.
This study tests a combination of two drugs—tislelizumab (an immunotherapy) and chemotherapy—to treat advanced stomach, gastroesophageal junction, or esophageal cancer that cannot be surgically removed. The trial focuses on recruiting patients from racial and ethnic minority communities to ensure the treatment is studied in diverse populations.
This trial tests a combination of chemotherapy and immunotherapy followed by targeted radiation before surgery for a specific type of esophageal cancer (T3N+). It aims to see if this approach can improve outcomes for patients whose tumors have not yet spread to other organs.
Hear when a new Esophageal Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.